ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas

Inclusion Criteria: * Patients diagnosed with astrocytoma grade IV WHO with histopathological/genetic confirmation who undergo the Stupp treatment * Age \> 18 years at diagnosis * Patients with access to complete preoperative, postoperative and follow up MRI studies, including: * Pre gadolinium T1-weighted MRI * Post gadolinium T1-wighted MRI * T2-weighted MRI * Fluid-Attenuated Inversion Recovery (FLAIR) * Dynamic Susceptibility Contrast (DSC) T2\*-weighted perfusion sequences * Diffusion Weighted Imaging (DWI) * Patients who undergo surgery with the possibility to collect samples from different regions of the tumor Exclusion Criteria: * Patient with congestive heart failure within 6 months prior to study entry (New York Heart Association \>= Grade 3) * Uncontrolled or significant cardiovascular disease, including: * Myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment * Uncontrolled angina within 6 months * Diagnosed or suspected congenital long QT syndrome * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) * Clinically significant abnormality on electrocardiogram (ECG) * Pulmonary disease including or greater than grade 2 dyspnea or laryngeal edema, grade 3 pulmonary edema or pulmonary hypertension according to CTCAE 4.03